3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
5
Thoracic
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
22
Melanoma
8
Triple Negative Breast Neoplasms
7
Neoplasm Metastasis
7
Carcinoma, Non-Small-Cell Lung
7
Ovarian Neoplasms
6
Colorectal Neoplasms
6
Uterine Cervical Neoplasms
3
Neoplasms
3
Carcinoma, Renal Cell
3
Carcinoma, Merkel Cell
3
Carcinoma, Hepatocellular
3
Breast Neoplasms, Male
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Skin Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Lymphoma
2
Head and Neck Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma, Transitional Cell
2
Uveal Melanoma
1
Turcot syndrome
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Recurrence
1
Rectal Neoplasms
1
Interventions
pembrolizumab
18
Trastuzumab
7
Docetaxel
7
Paclitaxel
6
Magnetic Resonance Spectroscopy
5
Taxes
4
Drug Therapy
4
Carboplatin
4
Specimen Handling
3
Psychiatric Rehabilitation
3
Polymerase Chain Reaction
3
Nivolumab
3
Injections
3
Fluorouracil
3
Fluorodeoxyglucose F18
3
Cyclophosphamide
3
Cisplatin
3
Capecitabine
3
Biopsy
3
poly ICLC
2
fludarabine
2
durvalumab
2
belinostat
2
atezolizumab
2
Radiotherapy
2
Oxaliplatin
2
Leucovorin
2
Lapatinib
2
Irinotecan
2
Interleukin-12
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
Interleukin-2
×
Breast
×
Clear all
NCT05086692
2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2
Recruiting
115 enrolled